Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension

Pharmacokinetic–Pharmacodynamic Relationships of Macitentan, a New Endothelin Receptor Antagonist, After Multiple Dosing in Healthy Korean Subjects

(2014) Li Young Ahn et al.   American Journal of Cardiovascular Drugs

Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects

(2014) Patricia N. Sidharta et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

(2014) Darren B. Taichman et al.   CHEST

Current Clinical Management of Pulmonary Arterial Hypertension

(2014) Roham T. Zamanian et al.   CIRCULATION RESEARCH

Investigation of the Effect of Macitentan on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

(2014) Patricia N. Sidharta et al.   CLINICAL DRUG INVESTIGATION

Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension

(2014) Marc Iglarz et al.   LIFE SCIENCES

The impact of drug–drug interactions on pulmonary arterial hypertension therapy

(2014) Rocco Ciracì et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects

(2014) Nicolas Lindegger et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Properly Diagnosing Pulmonary Arterial Hypertension

(2013) Ioana R. Preston   AMERICAN JOURNAL OF CARDIOLOGY

Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects

(2013) Jacob Atsmon et al.   CLINICAL PHARMACOKINETICS

Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro

(2013) Johanna Weiss et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

(2013) Jasper Dingemanse et al.   Expert Opinion On Drug Safety

Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment

(2013) Patricia N. Sidharta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Updated Treatment Algorithm of Pulmonary Arterial Hypertension

(2013) Nazzareno Galiè et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Definitions and Diagnosis of Pulmonary Hypertension

(2013) Marius M. Hoeper et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updated Clinical Classification of Pulmonary Hypertension

(2013) Gerald Simonneau et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Treatment Goals of Pulmonary Hypertension

(2013) Vallerie V. McLaughlin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

(2013) Tomás Pulido et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex

(2013) Shirin Bruderer et al.   PHARMACOLOGY

An Evaluation of Reproductive and Developmental Toxicity of Sitaxentan (Thelin) in Rats

(2012) David M. Cross et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist

(2012) Martin H. Bolli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Endothelin receptor antagonists for the treatment of pulmonary artery hypertension

(2012) Lewis J. Rubin   LIFE SCIENCES

Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells

(2012) John Gatfield et al.   PLoS One

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

(2012) Shirin Bruderer et al.   XENOBIOTICA

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

(2011) Shirin Bruderer et al.   AAPS Journal

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

(2011) Patricia N. Sidharta et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension

(2011) W.-T. N. Lee et al.   EUROPEAN RESPIRATORY JOURNAL

Liver toxicity of sitaxentan in pulmonary arterial hypertension

(2011) N. Galie et al.   EUROPEAN RESPIRATORY JOURNAL

Clinical Pharmacokinetics and Drug-Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension

(2011) Jürgen Venitz et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension

(2011) Dongmin Shao et al.   PHARMACOLOGICAL RESEARCH

Endothelin receptor antagonists – their role in pulmonary medicine

(2011) S. Boniface et al.   REVUE DES MALADIES RESPIRATOIRES

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

(2010) Jasper Dingemanse et al.   ANTIVIRAL THERAPY

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytesThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research.

(2010) J. Craig Hartman et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Pharmacotherapeutic Management of Pulmonary Arterial Hypertension

(2010) Joe R. Anderson et al.   Cardiology in Review

Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era

(2010) Marc Humbert et al.   CIRCULATION

Potential for Pharmacokinetic Interactions Between Ambrisentan and Cyclosporine

(2010) R Spence et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension

(2009) et al.   CIRCULATION

Bosentan

(2009) Sohita Dhillon   DRUGS

Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension

(2009) A. Lavelle et al.   EUROPEAN RESPIRATORY JOURNAL

Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?

(2009) M. M. Hoeper   EUROPEAN RESPIRATORY JOURNAL

Guidelines for the diagnosis and treatment of pulmonary hypertension

(2009) et al.   EUROPEAN RESPIRATORY JOURNAL

Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension

(2009) Ronald J. Oudiz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Endothelin receptor blockade in the management of pulmonary arterial hypertension: Selective and dual antagonism

(2009) Terence K. Trow et al.   RESPIRATORY MEDICINE

Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension

(2008) Laura C Price et al.   American Journal of Cardiovascular Drugs

Activation of ETB receptors regulates the abundance of ET-1 mRNA in vascular endothelial cells

(2008) N Farhat et al.   BRITISH JOURNAL OF PHARMACOLOGY

Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension

(2008) Hossein A. Ghofrani et al.   CIRCULATION

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

(2008) Nazzareno Galiè et al.   CIRCULATION

Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects

(2008) Rebecca E. Wrishko et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

(2008) M. Iglarz et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS